IBRX
Overvalued by 116.5% based on the discounted cash flow analysis.
Market cap | $5.36 Billion |
---|---|
Enterprise Value | $5.92 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.05 |
Beta | 2.6 |
Outstanding Shares | 691,567,961 |
Avg 30 Day Volume | 13,155,642 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -8.92 |
---|---|
PEG | -58.4 |
Price to Sales | - |
Price to Book Ratio | -3.83 |
Enterprise Value to Revenue | 19604.38 |
Enterprise Value to EBIT | -16.91 |
Enterprise Value to Net Income | -10 |
Total Debt to Enterprise | 0.12 |
Debt to Equity | -1.06 |
No data
No data
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...